Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2009-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1359/jbmr.081206PMID 19049336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone Degeneration and Recovery after Early and Late Bisphosphonate Treatment of Ovariectomized Wistar Rats Assessed by In Vivo Micro-Computed Tomography

  2008cited by this paper
• Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

  2008influential reference
• Long‐Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat

  2007cited by this paper
• Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.

  2007cited by this paper
• Update in osteoporosis and metabolic bone disorders.

  2007cited by this paper
• Finite Element Analysis Based on In Vivo HR‐pQCT Images of the Distal Radius Is Associated With Wrist Fracture in Postmenopausal Women

  2007cited by this paper
• LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST*

  2006cited by this paper
• Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors*

  2006cited by this paper
• Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP‐Stimulated Bone Formation

  2006cited by this paper
• Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity

  2006cited by this paper
• Osteocytes, strain detection, bone modeling and remodeling

  2005cited by this paper
• Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling*

  2005cited by this paper
• SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor*

  2005cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

  2003cited by this paper
• The natural history of sclerosteosis

  2003cited by this paper
• Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro.

  2002cited by this paper
• Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

  2001cited by this paper
• Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

  2001cited by this paper
• Glucocorticoids Inhibit Developmental Stage-specific Osteoblast Cell Cycle

  2000cited by this paper
• Toward a unifying theory of bone remodeling.

  2000cited by this paper
• Regional differences in cortical porosity in the fractured femoral neck.

  1999cited by this paper
• The Preventive and Interventional Effects of Raloxifene Analog (LY117018 HCL) on Osteopenia in Ovariectomized Rats

  1998cited by this paper
• Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.

  1996cited by this paper
• The structure of bone tissues and the cellular control of their deposition.

  1996cited by this paper
• The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.

  1995cited by this paper
• Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.

  1995cited by this paper
• Dual‐energy X‐ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

  1994cited by this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cited by this paper
• On the rat model of human osteopenias and osteoporoses.

  1992cited by this paper
• Osteon morphometry in females with femoral neck fractures.

  1992cited by this paper
• Candidates for the mechanosensory system in bone.

  1991cited by this paper
• The ovariectomized rat model of postmenopausal bone loss.

  1991cited by this paper
• Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats

  1990cited by this paper
• Sclerosteosis.

  1988cited by this paper
• Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

  1987cited by this paper
• Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

  1987cited by this paper
• Sclerosteosis

  1983cited by this paper
• In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria

  1983cited by this paper
• Printed in U.S.A. Copyright © 2001 by The Endocrine Society OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats

  year unknowncited by this paper
• The FASEB Journal express article 10.1096/fj.05-4221fje. Published online August 25, 2005. ©2005 FASEB

  year unknowncited by this paper

• Mathematical modeling of bone remodeling after surgical menopause.

  2026cites this paper
• Neutralizing hepatic apolipoprotein E enhances aged bone fracture healing

  2026cites this paper
• Dual inhibition of sclerostin and Notum induces synergistic osteoanabolic action in mice.

  2026cites this paper
• Genetic Influences and Targeted Treatments in Osteoporosis: A Systematic Review

  2025cites this paper
• Gsα Deficiency in Osteocytes Alters Craniofacial Growth and Enamel Mineralisation

  2025cites this paper
• In silico identification of sclerostin inhibitors

  2025cites this paper
• Anabolic effects of Sost deficiency partially offset Opg deficiency–induced catabolism in cortical bone

  2025cites this paper
• Renal Osteodystrophy: Multimodality Imaging

  2025cites this paper
• High-dose romosozumab promoted bone regeneration of critical-size ulnar defect filled with demineralized bone matrix in nonhuman primates

  2025cites this paper
• Notch signaling pathway in osteogenesis, bone development, metabolism, and diseases

  2025cites this paper
• Vitamin D3 deficiency and osteopenia in spastic paraplegia type 5 indicate impaired bone homeostasis

  2024cites this paper
• Romosozumab rescues impaired bone mass and strength in a murine model of diabetic kidney disease

  2024cites this paper
• Potential Metabolic Pathways Involved in Osteoporosis and Evaluation of Fracture Risk in Individuals with Diabetes

  2024cites this paper
• Affinity targeting of therapeutic proteins to the bone surface - local delivery of sclerostin neutralizing antibody enhances efficacy.

  2024cites this paper
• Τhe story of sclerostin inhibition: the past, the present, and the future

  2024cites this paper
• A mechanism of action-reflective, dual cell-based bioassay for determining the bioactivity of sclerostin-neutralizing antibodies.

  2024cites this paper
• Osteoblastgenic and Osteogenic Effects of KY-273 with CDK8/19 Inhibitory Activity in Bone Marrow Mesenchymal Stem Cells and Female Rats.

  2024cites this paper
• Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats

  2024cites this paper
• Decoding Osteoporosis: Understanding the Disease, Exploring Current and New Therapies and Emerging Targets.

  2024cites this paper
• Anti-sclerostin antibody therapy prevents post-ischemic osteonecrosis bone collapse via interleukin-6 association.

  2024cites this paper
• Comparative Evaluation of Sclerostin Levels in Gingival Crevicular Fluid of Periodontal Health and Disease before and after Nonsurgical Periodontal Therapy

  2024cites this paper
• Antisclerostin Effect on Osseointegration and Bone Remodeling

  2023cites this paper
• Antibodies to sclerostin or G-CSF receptor partially eliminate bone or marrow adipocyte loss, respectively, following vertical sleeve gastrectomy.

  2023cites this paper
• Impacts of residual 3D printing metal powders on immunological response and bone regeneration: an in vivo study

  2023cites this paper
• Sclerostin blockade promotes bone metastases of Wnt‐responsive breast cancer cells

  2023cites this paper
• Anti‐Siglec‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats

  2023cites this paper
• Wnt1 induces osteoblastic changes in a well‐established osteolytic skeletal metastatic model derived from breast cancer

  2023cites this paper
• Yeast Hydrolysate and Postmenopausal Osteoporosis

  2023cites this paper
• Biotecnología aplicada al diagnóstico y tratamiento de la osteoporosis. Avances en biofármacos, bioterapias y biomarcadores. Parte 2

  2023cites this paper
• Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis

  2023cites this paper
• Effects of adipocyte-specific Dkk1 deletion on bone homeostasis and obesity-induced bone loss in male mice

  2023cites this paper
• Romosozumab in osteoporosis: yesterday, today and tomorrow

  2023cites this paper
• Crosstalk between Adult Hippocampal Neurogenesis and Its Role in Alzheimer's Disease.

  2023cites this paper
• Therapeutic effects of isoquercetin on ovariectomy-induced osteoporosis in mice

  2023cites this paper
• Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone

  2023cites this paper
• Osteogenic Effects of KY-054, a Novel Coumarin Derivative on Femur Cortical Bone in Ovariectomized Female Rats.

  2023cites this paper
• Rational engineering of glycosaminoglycan-based Dickkopf-1 scavengers to improve bone regeneration.

  2023cites this paper
• Regulation of the Osteocyte Secretome with Aging and Disease

  2023cites this paper
• Why Animal Experiments Are Still Indispensable in Bone Research: A Statement by the European Calcified Tissue Society

  2023cites this paper
• Assessment of serum Sclerostin level and its relationship to Assessment of serum Sclerostin level and its relationship to coronary calcifications in chronic kidney disease patients coronary calcifications in chronic kidney disease patients

  2023cites this paper
• Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review

  2022cites this paper
• Juvenile Bone Toxicity: Study Considerations, Regulations, and Techniques for Assessment

  2022cites this paper
• Where is bone science taking us?

  2022cites this paper
• Comparative evaluation of sclerostin levels in gingival crevicular fluid of periodontal health and disease before and after nonsurgical periodontal therapy

  2022cites this paper
• Therapeutic approaches to activate the canonical Wnt pathway for bone regeneration

  2022cites this paper
• Nanotechnology for targeted drug delivery to treat osteoporosis.

  2022cites this paper
• Monoporous Microsphere as a Dynamically Movable Drug Carrier for Osteoporotic Bone Remodeling

  2022cites this paper
• Bone Health in Chronic Kidney Disease

  2022cites this paper
• p53 deficiency promotes bone regeneration by functional regulation of mesenchymal stromal cells and osteoblasts

  2022cites this paper
• Wnt Pathway Extracellular Components and Their Essential Roles in Bone Homeostasis

  2022cites this paper
• Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues

  2022cites this paper
• Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis.

  2022cites this paper
• Expression of mir-29a-5p, sclerostin and fetuin-A in patients with chronic kidney disease and their correlation with vascular calcification.

  2022cites this paper
• Management of Osteoporosis Medication after Osteoporotic Fracture

  2022cites this paper
• Drug discovery of sclerostin inhibitors

  2022cites this paper
• Induction of osteogenesis by bone-targeted Notch activation

  2022cites this paper
• Effects of low dose doxycycline and caffeic acid phenethyl ester on sclerostin and bone morphogenic protein-2 expressions in experimental periodontitis

  2022cites this paper
• Oncostatin M receptor regulates osteoblast differentiation via extracellular signal-regulated kinase/autophagy signaling

  2022cites this paper
• Bridging the gap: Compressing non-unions for proper cellular signaling

  2022cites this paper
• Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice.

  2022cites this paper
• Endocrine Functions of Sclerostin.

  2022cites this paper
• Temporal changes in cortical microporosity during estrogen deficiency associated with perilacunar resorption and osteocyte apoptosis: A pilot study

  2022cites this paper
• Oral Biosciences: The annual review 2021.

  2022cites this paper
• Suppression of Sost/Sclerostin and Dickkopf‐1 Augment Intervertebral Disc Structure in Mice

  2022cites this paper
• Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders

  2022cites this paper
• Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton

  2022cites this paper
• Romosozumab: Optimizing the Anabolic Window

  2022cites this paper
• The effect of osteoporosis treatment on bone mass.

  2022cites this paper
• WNT signaling in skeletal homeostasis and diseases

  2021cites this paper
• Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis

  2021cites this paper
• Low Level of Serum Sclerostin in Adult Patients with Tumor-induced Osteomalacia Comparing with X-linked Hypophosphatemia.

  2021cites this paper
• Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse

  2021cites this paper
• Skeletal Aging and Osteoporosis: Cellular Senescence and Beyond

  2021cites this paper
• Molecular enhancement of fracture healing - Is there a role for bone Morphogenetic Protein-2, Parathyroid Hormone, statins, or sclerostin-antibodies?

  2021cites this paper
• The diverse origin of bone‐forming osteoblasts

  2021cites this paper
• Anti-Sklerostin-Therapie aus nephrologischer Sicht – mit einem Fokus auf kardiovaskuläre Sicherheit

  2021cites this paper
• Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis

  2021cites this paper
• Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting

  2021cites this paper
• Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application

  2021cites this paper
• Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics

  2021cites this paper
• Physiological and Pharmacological Roles of PTH and PTHrP in Bone using their Shared Receptor, PTH1R.

  2021cites this paper
• SIRT1, a promising regulator of bone homeostasis.

  2021cites this paper
• Icariin Promotes the Osteogenesis of Bone Marrow Mesenchymal Stem Cells through Regulating Sclerostin and Activating the Wnt/β-Catenin Signaling Pathway

  2021cites this paper
• Dihydroartemisinin attenuates osteoarthritis by inhibiting abnormal bone remodeling and angiogenesis in subchondral bone

  2021cites this paper
• A Biphasic Feature of Gli1+-Mesenchymal Progenitors during Cementogenesis That Is Positively Controlled by Wnt/β-Catenin Signaling

  2021cites this paper
• Genetics and Genomics of SOST: Functional Analysis of Variants and Genomic Regulation in Osteoblasts

  2021cites this paper
• Sclerostin and Its Role as a Bone Modifying Agent in Periodontal Disease.

  2021cites this paper
• Sclerostin Protects Against Vascular Calcification Development in Mice

  2021cites this paper
• Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases.

  2021cites this paper
• Regulatory Perspectives on Juvenile Animal Toxicologic Pathology

  2021cites this paper
• Anabolic and Emerging Therapies

  2021cites this paper
• Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease

  2021cites this paper
• Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review.

  2021cites this paper
• Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption

  2021cites this paper
• Diaphyseal and Metaphyseal Modeling Defects—Clinical Findings and Identification of WRAP53 Deficiency in Craniometadiaphyseal Dysplasia

  2021cites this paper
• ASPECTS OF INTERCELLULAR COMMUNICATION IN BONE AND IMPLICATIONS IN THERAPY.

  2021cites this paper
• Osteocyte Mechanosensing following short-term and long-term treatment with Sclerostin antibody.

  2021cites this paper
• Effects of sclerostin antibody on bone healing

  2021cites this paper
• Anti-sclerostin treatment from a nephrological perspective — with a focus on cardiovascular safety

  2021cites this paper
• Reduction of SOST gene promotes bone formation through the Wnt/β‐catenin signalling pathway and compensates particle‐induced osteolysis

  2020cites this paper